Galectin Therapeutics
GALT
59 hedge funds and large institutions have $11.3M invested in Galectin Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 8 closing their positions.
74% more call options, than puts
Call options by funds: $327K | Put options by funds: $188K
22% more capital invested
Capital invested by funds: $9.26M → $11.3M (+$2.06M)
0.2% less ownership
Funds ownership: 11.89% → 11.69% (-0.2%)
2% less funds holding
Funds holding: 60 → 59 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.9K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$33K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$25K |
| 4 |
VF
Virtu Financial
New York
|
+$24K |
| 5 |
Mariner
Overland Park,
Kansas
|
+$21.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$61.4K |
| 2 |
Morgan Stanley
New York
|
-$39.8K |
| 3 |
Renaissance Technologies
New York
|
-$36K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$32.6K |
| 5 |
Millennium Management
New York
|
-$31K |
GALT Hedge Fund Activity: Q3 2022 in Review
59 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2022, worth a combined $11.3M — up 22% from $9.26M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GALT and 7 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.9K. The largest seller was Geneos Wealth Management, cutting an estimated $61.4K.
- 59 institutional investors held Galectin Therapeutics (GALT) as of Q3 2022, down from 60 in Q2 2022.
- Funds reported $11.3M of Galectin Therapeutics stock for Q3 2022, up 22% quarter-over-quarter.
- 7 funds opened new Galectin Therapeutics positions in Q3 2022 and 8 closed out, a net change of -1 holder.
- The largest Galectin Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $33.9K added.
- The largest Galectin Therapeutics seller in Q3 2022 was Geneos Wealth Management, an estimated $61.4K sold.
Based on aggregated 13F filings for Q3 2022.